Market Cap (In EUR)
187.66 Million
Revenue (In EUR)
14.19 Million
Net Income (In EUR)
-3.35 Million
Avg. Volume
777.22 Thousand
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.494-2.385
- PE
- -41.43
- EPS
- -0.07
- Beta Value
- 0.646
- ISIN
- -
- CUSIP
- -
- CIK
- -
- Shares
- 64711100.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Carlos Manuel Buesa Arjol
- Employee Count
- -
- Website
- https://www.oryzon.com
- Ipo Date
- 2015-12-14
- Details
- Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
More Stocks
-
ENNPFEnbridge Inc
ENNPF
-
OLEDeoleo, S.A.
OLE
-
FPRUYFraport AG
FPRUY
-
NRGN
-
PMCCF
-
ENDGF
-
LRGR
-
STLTECHSterlite Technologies Limited
STLTECH